<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00067119</url>
  </required_header>
  <id_info>
    <org_study_id>VAC GRAFT</org_study_id>
    <secondary_id>U01DK058982</secondary_id>
    <nct_id>NCT00067119</nct_id>
  </id_info>
  <brief_title>Aggrenox Prevention of Access Stenosis</brief_title>
  <acronym>GRAFT</acronym>
  <official_title>Effect of Dipyridamole Plus Aspirin on Hemodialysis Graft Patency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maine Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baystate Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CAMC Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Louis University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tyler Nephrology Associates</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vascular Surgery Associates LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs
      primary unassisted patency in newly created arteriovenous grafts. This record previously
      included information for both the GRAFT and FISTULA trials.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2003</start_date>
  <completion_date type="Actual">January 31, 2008</completion_date>
  <primary_completion_date type="Actual">January 31, 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">649</enrollment>
  <condition>Kidney Failure</condition>
  <arm_group>
    <arm_group_label>Aggrenox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aggrenox</intervention_name>
    <arm_group_label>Aggrenox</arm_group_label>
    <other_name>Dipyridamole plus aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Age 18-21 depending on state regulations

          -  Life expectancy of at least six months

          -  Chronic renal failure with anticipated start of hemodialysis within six months of
             enrollment, or current dialysis dependence

          -  A new or planned arteriovenous (AV) graft placed in any location for the purpose of
             hemodialysis. (Any type of graft material and any configuration of the access is
             acceptable).

          -  The patient is expected to stay at a participating dialysis facility for at least 6
             months.

          -  The patient's physician(s) will allow the patient to participate.

          -  Ability to give informed consent.

        Exclusion Criteria:

          -  Women must not be pregnant, breastfeeding, or plan to be pregnant during the course of
             the study.

          -  The presence of ongoing bleeding.

          -  The presence of a known bleeding disorder (e.g., hemophilia or von Willebrand's
             disease).

          -  Recent bleeding episode requiring transfusion within 12 weeks of entry.

          -  The presence of acute ulcer disease. Acute ulcer disease is defined as a new diagnosis
             of peptic disease including esophagitis, gastritis, or ulcer or the initiation of
             treatment with proton pump inhibitors, H2 blockers or therapy for Helicobacter pylori
             within three months prior to obtaining consent.

          -  Known allergy or adverse reaction to Aggrenox or any of its study components
             (dipyridamole and aspirin).

          -  Required use of warfarin, dipyridamole, non-steroidal antiinflammatory drugs or other
             antiplatelet agents other than aspirin.

          -  Current uncontrolled hypertension with systolic blood pressure in excess of 200 mm Hg
             or diastolic blood pressure in excess of 115 mm Hg.

          -  Baseline platelet count less than 75,000/mm3.

          -  Known advanced liver disease with decompensated cirrhosis, jaundice, ascites or
             bleeding varices.

          -  Current problem with substance abuse.

          -  Concurrent participation in another medical intervention trial.

          -  Anticipated non-compliance with medical care based on physician judgment.

          -  Patient refusal.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John W Kusek, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>NIDDK - Telephone: 301-594-7717; Email: kusekj@ep.niddk.nih.gov</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Catherine Meyers, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>NIDDK - Telephone: 301-451-4901; Email: meyersc@extra.niddk.nih.gov</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Dixon BS, Beck GJ, Dember LM, Depner TA, Gassman JJ, Greene T, Himmelfarb J, Hunsicker LG, Kaufman JS, Lawson JH, Meyers CM, Middleton JP, Radeva M, Schwab SJ, Whiting JF, Feldman HI; DAC Study Group. Design of the Dialysis Access Consortium (DAC) Aggrenox Prevention Of Access Stenosis Trial. Clin Trials. 2005;2(5):400-12.</citation>
    <PMID>16317809</PMID>
  </reference>
  <results_reference>
    <citation>Dixon BS, Beck GJ, Vazquez MA, Greenberg A, Delmez JA, Allon M, Dember LM, Himmelfarb J, Gassman JJ, Greene T, Radeva MK, Davidson IJ, Ikizler TA, Braden GL, Fenves AZ, Kaufman JS, Cotton JR Jr, Martin KJ, McNeil JW, Rahman A, Lawson JH, Whiting JF, Hu B, Meyers CM, Kusek JW, Feldman HI; DAC Study Group. Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med. 2009 May 21;360(21):2191-201. doi: 10.1056/NEJMoa0805840.</citation>
    <PMID>19458364</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2003</study_first_submitted>
  <study_first_submitted_qc>August 12, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2003</study_first_posted>
  <last_update_submitted>September 18, 2017</last_update_submitted>
  <last_update_submitted_qc>September 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Graft Failure</keyword>
  <keyword>Access Blood Flow Monitoring</keyword>
  <keyword>Clinical Trial Vascular Access</keyword>
  <keyword>Fistula Failure</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Vascular Access</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Dipyridamole</mesh_term>
    <mesh_term>Aspirin, Dipyridamole Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be available at the National Institute of Diabetes Digestive and Kidney Diseases (NIDDK) Central Repository</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

